Colorectal cancer screening in patients with inherited bleeding disorders: high cancer detection rate in hemophilia patients.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
05 2023
Historique:
received: 19 10 2022
revised: 01 12 2022
accepted: 03 12 2022
medline: 2 5 2023
pubmed: 26 1 2023
entrez: 25 1 2023
Statut: ppublish

Résumé

The population-based colorectal cancer (CRC) screening program in individuals aged 55 to 75 years in the Netherlands uses fecal immunochemical testing (FIT), to detect hemoglobin in feces, followed by colonoscopy in individuals with a positive FIT. The objectives of this study are to assess the false-positive rate, detection rate, and positive predictive value of FIT for CRC and advanced adenoma (AA) in patients with Von Willebrand disease (VWD) or hemophilia. We performed a multicenter, nationwide cross-sectional study embedded in 2 nationwide studies on VWD and hemophilia in the Netherlands. In total, 493 patients with hemophilia (n = 329) or VWD (n = 164) were included, of whom 351 patients participated in the CRC screening program (71.2%). FIT positivity and false-positive rate in patients with hemophilia and VWD were significantly higher than those in the general population (14.8% vs. 4.3%, p < .001 and 10.3% vs. 2.3%, p <.001, respectively). In patients with hemophilia, the detection rate of CRC/AA was significantly higher than that in the general male population (4.5% vs. 1.8%, p = .02), and the positive predictive value of FIT for CRC/AA was comparable (32.3% vs. 39.7%, n.s.). In patients with VWD, the detection rate was similar to that of the general population (0.8% vs. 1.4%, n.s.), whereas the positive predictive value was significantly lower than that in the general population (6.3% vs. 36.8%, p = .02). This study indicates that despite a high false-positive rate of FIT in patients with inherited bleeding disorders, the detection rate of CRC and/or AA in hemophilia patients is high. FIT performs different in patients with hemophilia or VWD compared with the general population.

Sections du résumé

BACKGROUND
The population-based colorectal cancer (CRC) screening program in individuals aged 55 to 75 years in the Netherlands uses fecal immunochemical testing (FIT), to detect hemoglobin in feces, followed by colonoscopy in individuals with a positive FIT.
OBJECTIVES
The objectives of this study are to assess the false-positive rate, detection rate, and positive predictive value of FIT for CRC and advanced adenoma (AA) in patients with Von Willebrand disease (VWD) or hemophilia.
METHODS
We performed a multicenter, nationwide cross-sectional study embedded in 2 nationwide studies on VWD and hemophilia in the Netherlands.
RESULTS
In total, 493 patients with hemophilia (n = 329) or VWD (n = 164) were included, of whom 351 patients participated in the CRC screening program (71.2%). FIT positivity and false-positive rate in patients with hemophilia and VWD were significantly higher than those in the general population (14.8% vs. 4.3%, p < .001 and 10.3% vs. 2.3%, p <.001, respectively). In patients with hemophilia, the detection rate of CRC/AA was significantly higher than that in the general male population (4.5% vs. 1.8%, p = .02), and the positive predictive value of FIT for CRC/AA was comparable (32.3% vs. 39.7%, n.s.). In patients with VWD, the detection rate was similar to that of the general population (0.8% vs. 1.4%, n.s.), whereas the positive predictive value was significantly lower than that in the general population (6.3% vs. 36.8%, p = .02).
CONCLUSION
This study indicates that despite a high false-positive rate of FIT in patients with inherited bleeding disorders, the detection rate of CRC and/or AA in hemophilia patients is high. FIT performs different in patients with hemophilia or VWD compared with the general population.

Identifiants

pubmed: 36696188
pii: S1538-7836(22)12805-9
doi: 10.1016/j.jtha.2022.12.004
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1177-1188

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Eva K Kempers (EK)

Department of Hematology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Calvin B van Kwawegen (CB)

Department of Hematology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Joke de Meris (J)

Netherlands Hemophilia Society, Leiden, The Netherlands.

Manon C W Spaander (MCW)

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Saskia E M Schols (SEM)

Department of Hematology, Radboud University Medical Center, Nijmegen and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, The Netherlands.

Paula F Ypma (PF)

Department of Hematology, Haga Hospital, The Hague, The Netherlands.

Floor C J I Heubel-Moenen (FCJI)

Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands.

Lize F D van Vulpen (LFD)

Benign Hematology Center, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.

Michiel Coppens (M)

Amsterdam UMC Location University of Amsterdam, Vascular Medicine, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands.

Johanna G van der Bom (JG)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Karin Fijnvandraat (K)

Amsterdam UMC Location University of Amsterdam, Department of Pediatric Hematology, Amsterdam, The Netherlands; Sanquin Research, Department of Molecular Hematology, Amsterdam, The Netherlands; Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Karina Meijer (K)

Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.

Jeroen Eikenboom (J)

Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.

Samantha C Gouw (SC)

Amsterdam UMC Location University of Amsterdam, Department of Pediatric Hematology, Amsterdam, The Netherlands.

Frank W G Leebeek (FWG)

Department of Hematology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Marieke J H A Kruip (MJHA)

Department of Hematology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Electronic address: m.kruip@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH